Your browser is no longer supported. Please, upgrade your browser.
Settings
XFOR X4 Pharmaceuticals, Inc. daily Stock Chart
XFOR [NASD]
X4 Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-16.18 Insider Own2.00% Shs Outstand12.44M Perf Week-3.99%
Market Cap143.68M Forward P/E- EPS next Y-4.21 Insider Trans- Shs Float12.14M Perf Month-23.00%
Income-45.10M PEG- EPS next Q-1.07 Inst Own61.40% Short Float1.89% Perf Quarter-21.59%
Sales3.50M P/S41.05 EPS this Y-26.70% Inst Trans0.05% Short Ratio8.24 Perf Half Y-17.20%
Book/sh7.30 P/B1.58 EPS next Y14.80% ROA-64.90% Target Price24.00 Perf Year16.67%
Cash/sh7.25 P/C1.59 EPS next 5Y- ROE-103.00% 52W Range6.90 - 29.46 Perf YTD-17.03%
Dividend- P/FCF- EPS past 5Y- ROI-155.50% 52W High-60.86% Beta-
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low67.10% ATR0.79
Employees15 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)34.75 Volatility4.39% 7.32%
OptionableNo Debt/Eq0.27 EPS Q/Q80.00% Profit Margin- Rel Volume0.06 Prev Close11.55
ShortableYes LT Debt/Eq0.23 EarningsAug 26 Payout- Avg Volume27.88K Price11.53
Recom1.70 SMA20-8.75% SMA50-9.67% SMA200-27.54% Volume230 Change-0.17%
Jun-07-19Initiated Stifel Buy $27
Jun-05-19Initiated Cowen Outperform
Sep-30-19 02:45AM  X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients Business Wire
Sep-27-19 05:10PM  X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-23-19 08:30AM  X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors Business Wire -12.43%
Sep-18-19 08:30AM  X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development Business Wire
Sep-17-19 08:30AM  X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences Business Wire
Sep-12-19 08:30AM  X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress Business Wire
Aug-29-19 04:30PM  X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-06-19 08:30AM  X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-30-19 08:30AM  X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome Business Wire +8.15%
Jul-24-19 08:30AM  X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences Business Wire
Jun-26-19 08:30AM  X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome Business Wire
Jun-12-19 08:30AM  X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease Business Wire
May-15-19 08:30AM  X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenströms Macroglobulinemia Business Wire -7.43%
Apr-24-19 08:30AM  X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer Business Wire +6.06%
Apr-12-19 09:29AM  X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants Business Wire -16.75%
Apr-11-19 04:00PM  X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants Business Wire -8.48%
Apr-02-19 08:30AM  X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors Business Wire
Apr-01-19 08:30AM  X4 Pharmaceuticals Provides Business and Clinical Development Update Business Wire
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenstrom macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.